AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 21 min read$ACOG

Opaleye Management Inc. purchased $166K of ACOG (indirect holdings)

Opaleye Management Inc. purchased 19,050 indirectly-held shares of Alpha Cognition Inc. (ACOG) at $8.69 ($0.17M total) on 2026-10-01.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published Oct 2, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ACOG
Neutral
medium confidence
Mentioned
$ACOG
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACOGNeutralLow
01

Why it matters

The insider transaction is a primary disclosure but modest in size, offering limited trading impetus.

02

Market read

A small insider buy that may marginally influence ACOG's stock price.

03

What to watch

Potential upcoming clinical data or financing events not disclosed.

Relevance 5/10Novelty 5/10Timing: after-hours filing

Background

Alpha Cognition Inc. is a biotech firm listed on NASDAQ. Opaleye Management Inc. holds a 10% stake and filed a Form 4 indicating an additional purchase.

Company-level read

Ticker impact

$ACOGNeutralMedium confidence
Context

Form 4 shows Opaleye Management Inc., a 10% owner, purchased 19,050 shares of Alpha Cognition Inc. for $165,634, increasing its stake to over 3.2 million shares.

Expected impact

likely slight upward pressure as market prices in insider confidence

Evidence & confidence

The purchase is relatively small in absolute terms and follows a prior large holding, so impact is limited.

Market effects

Sector

Minimal effect on the broader biotech sector.

Regional

No significant regional impact.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The purchase may be a routine portfolio adjustment rather than a confidence signal.

Key entities

  • Company
    Alpha Cognition Inc.

    Biotech company whose shares were purchased.

  • Investor
    Opaleye Management Inc.

    10% owner filing the Form 4.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ACOG insider trading history →

Related articles

AUG 15
$ACOGMed

Alpha Cognition Q2 Earnings Call Highlights

Alpha Cognition (NASDAQ:ACOG) said ZUNVEYL demand rose each month in Q2, with June the strongest month to date, and management attributed growth to demand rather than wholesaler or pharmacy stocking. Payer formulary activation lagged expectations, with payer access the key near-term friction. The company reported BEACON study positive top-line results, lowered 2026 operating expense guidance to $50M-$54M, and had $41.4M cash as of June 30.

yahoo.com6 min
AUG 14
$ACOGHighAI 9/10

Why is Alpha Cognition stock surging today?

Alpha Cognition (ACOG) shares rose about 12.1% pre-open after its Q2 2026 earnings call. ZUNVEYL net product revenue was about $6.0M, up 71% sequentially and from $1.7M in Q2 2025. Net loss narrowed to $8.8M ($0.40/share). Gross product margin was ~94%, and full-year 2026 operating expense guidance was cut to $50M-$54M; profitability target remains 2027.

investing.com4 min
JUL 29
$ACOGMed

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc. (NASDAQ: ACOG) said the European Patent Office granted a European patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in treating mild-to-moderate Alzheimer’s disease. The patent covers specific solid form, compositions, manufacturing and medical-use claims, with potential protection into 2042, subject to requirements.

thestarphoenix.com3 min